Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free IKT Stock Alerts

Inhibikase Therapeutics (IKT) Competitors

Inhibikase Therapeutics logo
$2.50 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.50 0.00 (-0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

IKT vs. SPTX, EYPT, CALT, CRON, and ANRO

Should you buy Inhibikase Therapeutics stock or one of its competitors? Inhibikase Therapeutics's main competitors and comparable companies include Seaport Therapeutics (SPTX), Eyepoint Pharmaceuticals (EYPT), Calliditas Therapeutics AB (publ) (CALT), Cronos Group (CRON), and Alto Neuroscience (ANRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inhibikase Therapeutics compare to Seaport Therapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Seaport Therapeutics presently has a consensus price target of $38.40, suggesting a potential upside of 54.65%. Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Seaport Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seaport Therapeutics
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30
Inhibikase Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.00

Inhibikase Therapeutics has higher revenue and earnings than Seaport Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seaport TherapeuticsN/AN/A-$74.88M-$12.12N/A
Inhibikase Therapeutics$260K1,341.73-$48.26M-$0.43N/A

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Seaport Therapeutics had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Seaport Therapeutics and 1 mentions for Inhibikase Therapeutics. Seaport Therapeutics' average media sentiment score of 0.36 beat Inhibikase Therapeutics' score of 0.00 indicating that Seaport Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Seaport Therapeutics Neutral
Inhibikase Therapeutics Neutral

Seaport Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seaport TherapeuticsN/A N/A N/A
Inhibikase Therapeutics N/A -42.80%-40.58%

Summary

Inhibikase Therapeutics beats Seaport Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Eyepoint Pharmaceuticals?

Inhibikase Therapeutics (NASDAQ:IKT) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Inhibikase Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Inhibikase Therapeutics' return on equity of -42.80% beat Eyepoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibikase TherapeuticsN/A -42.80% -40.58%
Eyepoint Pharmaceuticals -10,994.73%-135.81%-108.35%

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inhibikase Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

Inhibikase Therapeutics currently has a consensus price target of $5.40, indicating a potential upside of 116.00%. Eyepoint Pharmaceuticals has a consensus price target of $28.11, indicating a potential upside of 461.10%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.00
Eyepoint Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.45

Inhibikase Therapeutics has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase Therapeutics$260K1,341.73-$48.26M-$0.43N/A
Eyepoint Pharmaceuticals$2.79M154.92-$231.96M-$3.74N/A

In the previous week, Eyepoint Pharmaceuticals had 20 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 21 mentions for Eyepoint Pharmaceuticals and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Eyepoint Pharmaceuticals' score of -0.02 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Inhibikase Therapeutics Neutral
Eyepoint Pharmaceuticals Neutral

Summary

Inhibikase Therapeutics beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Inhibikase Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Inhibikase Therapeutics' return on equity of -42.80% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
Inhibikase Therapeutics N/A -42.80%-40.58%

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Inhibikase Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Inhibikase Therapeutics Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Inhibikase Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
Inhibikase Therapeutics$260K1,341.73-$48.26M-$0.43N/A

Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Inhibikase Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.00

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Summary

Inhibikase Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Cronos Group currently has a consensus price target of $2.30, indicating a potential downside of 34.47%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Inhibikase Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.00

Cronos Group has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Cronos Group has a net margin of 39.08% compared to Inhibikase Therapeutics' net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group39.08% 4.85% 4.62%
Inhibikase Therapeutics N/A -42.80%-40.58%

In the previous week, Cronos Group had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Cronos Group and 1 mentions for Inhibikase Therapeutics. Cronos Group's average media sentiment score of 0.46 beat Inhibikase Therapeutics' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company Overall Sentiment
Cronos Group Neutral
Inhibikase Therapeutics Neutral

Cronos Group has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$146.59M8.88-$9.45M$0.2017.55
Inhibikase Therapeutics$260K1,341.73-$48.26M-$0.43N/A

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cronos Group beats Inhibikase Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Inhibikase Therapeutics' return on equity of -42.80% beat Alto Neuroscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Alto NeuroscienceN/A -46.46% -39.09%
Inhibikase Therapeutics N/A -42.80%-40.58%

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inhibikase Therapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alto NeuroscienceN/AN/A-$63.24M-$2.42N/A
Inhibikase Therapeutics$260K1,341.73-$48.26M-$0.43N/A

Alto Neuroscience has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Alto Neuroscience presently has a consensus price target of $37.25, suggesting a potential upside of 2.91%. Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Alto Neuroscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alto Neuroscience
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Inhibikase Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.00

In the previous week, Alto Neuroscience had 18 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 19 mentions for Alto Neuroscience and 1 mentions for Inhibikase Therapeutics. Alto Neuroscience's average media sentiment score of 0.95 beat Inhibikase Therapeutics' score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company Overall Sentiment
Alto Neuroscience Positive
Inhibikase Therapeutics Neutral

Summary

Inhibikase Therapeutics beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKT vs. The Competition

Export
MetricInhibikase TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$348.85M$12.52B$7.31B$12.78B
Dividend YieldN/A2.61%2.54%10.79%
P/E Ratio-5.81778.14271.7824.19
Price / Sales1,341.73961.13696.74129.13
Price / CashN/A15.4728.8736.86
Price / Book1.0910.5711.346.52
Net Income-$48.26M$2.80B$3.46B$347.97M
7 Day Performance4.17%3.95%3.23%1.57%
1 Month Performance7.30%6.54%8.82%5.24%
1 Year PerformanceN/A8.76%27.70%17.87%

Inhibikase Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IKT
Inhibikase Therapeutics
1.5302 of 5 stars		$2.50
flat		$5.40
+116.0%		N/A$348.85M$260KN/A6
SPTX
Seaport Therapeutics
2.9261 of 5 stars		$24.40
+0.7%		$38.40
+57.4%		N/A$1.30BN/AN/AN/A
EYPT
Eyepoint Pharmaceuticals
2.3525 of 5 stars		$4.87
-67.0%		$40.33
+728.2%		-58.8%$1.27B$31.37MN/A120
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat		N/AN/A$1.19B$1.60BN/A180
CRON
Cronos Group
1.6712 of 5 stars		$3.15
+0.3%		$2.30
-27.0%		+31.2%$1.16B$146.59M15.75450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel